Stephens Reaffirms Overweight Rating for Guardant Health (NASDAQ:GH)

Guardant Health (NASDAQ:GH)‘s stock had its “overweight” rating reiterated by research analysts at Stephens in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $55.00 price target on the stock. Stephens’ target price would suggest a potential upside of 21.82% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. The Goldman Sachs Group upped their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Guggenheim reiterated a “buy” rating and set a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Raymond James restated an “outperform” rating and set a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Canaccord Genuity Group upped their target price on Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Finally, JPMorgan Chase & Co. raised their price objective on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $48.95.

Guardant Health Stock Down 1.5 %

NASDAQ GH opened at $45.15 on Wednesday. The firm has a 50-day moving average price of $44.53 and a two-hundred day moving average price of $34.11. Guardant Health has a 12-month low of $15.81 and a 12-month high of $50.89. The company has a market capitalization of $5.57 billion, a P/E ratio of -12.68 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The company had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Equities analysts expect that Guardant Health will post -2.9 EPS for the current year.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. 111 Capital acquired a new stake in Guardant Health in the fourth quarter valued at approximately $254,000. Polar Asset Management Partners Inc. grew its position in Guardant Health by 1,902.2% in the 4th quarter. Polar Asset Management Partners Inc. now owns 454,500 shares of the company’s stock valued at $13,885,000 after purchasing an additional 431,800 shares during the period. GF Fund Management CO. LTD. bought a new stake in Guardant Health during the 4th quarter valued at $79,000. Twinbeech Capital LP acquired a new position in Guardant Health during the fourth quarter worth $367,000. Finally, Two Sigma Advisers LP lifted its stake in shares of Guardant Health by 96.7% in the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock valued at $70,742,000 after buying an additional 1,138,300 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.